Clinical Trials Sponsored by Dina latif

Total 1625 results

Shanghai Huaota Biopharmaceutical Co., Ltd.
M.D. Anderson Cancer Center; Dana-Farber Cancer Institute; Gabrail Cancer Center...

Recruiting

A Study of HB0045 Injection in Patients With Advanced Solid Tumors

Solid Tumor, Adult

United States
Beth Israel Deaconess Medical Center
National Institute on Alcohol Abuse and Alcoholism (NIAAA); Dana-Farber Cancer...

Completed

Alcohol and Breast Cancer (ABC) Trial

Breast Cancer | Aromatase Inhibitors | ER+ Breast Cancer

United States
Dana-Farber Cancer Institute
Massachusetts General Hospital; GlaxoSmithKline; Beth Israel Deaconess Medical... and other collaborators

Completed

Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer

Small Cell Lung Cancer | Lung Cancer | SCLC

United States
Beth Israel Deaconess Medical Center
National Institutes of Health (NIH); Teva Pharmaceuticals USA

Terminated

Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML)

Chronic Myelogenous Leukemia

United States
Massachusetts General Hospital
Bayer; Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Brigham...

Terminated

CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's Lymphoma

Lymphoma, B-Cell | Lymphoma, Non-Hodgkin | Lymphoma, Diffuse

United States
Dana-Farber Cancer Institute
Beth Israel Deaconess Medical Center; Genentech, Inc.; Brigham and Women's Hospital and other collaborators

Terminated

CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia

Waldenstrom's Macroglobulinemia

United States
Massachusetts General Hospital
Sanofi; Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; North...

Withdrawn

A Randomized Study to Evaluate the Effect of Two Different Doses of Enoxaparin Sodium in Combination With Standard Chemotherapy in Patients With Stage Small Cell Lung Cancer (SCLC)

Small Cell Lung Cancer

United States
Dana-Farber Cancer Institute
National Cancer Institute (NCI); Beth Israel Deaconess Medical Center; Brigham...

Completed

Donor Dendritic Cells And Donor Lymphocytes in Patients With Relapsed Hematologic Malignancies After Allogeneic Transplant

Hematologic Malignancy

United States
Dana-Farber Cancer Institute
Massachusetts General Hospital; Sanofi; Beth Israel Deaconess Medical Center; Brigham...

Completed

Study of Taxotere, Cisplatin, 5-Fluorouracil, and Leucovorin for Squamous Cell Carcinoma of the Head and Neck

Squamous Cell Carcinoma | Carcinoma of Head and/or Neck

United States
Brigham and Women's Hospital
Dana-Farber Cancer Institute; Duke University; H. Lee Moffitt Cancer Center and...

Not yet recruiting

Positive Psychology Intervention for Hematopoietic Stem Cell Transplantation Survivors (PATH-4)

Hematopoietic Stem Cell Transplant

United States
Harvard School of Public Health (HSPH)
Boston University; Dana-Farber Cancer Institute; Dimagi Inc.; Narotam Sekhsaria...

Not yet recruiting

Adapting and Evaluating a Brief Advice Tobacco Intervention in High-Reach, Low-Resource Settings in India (SWASTH)

Tobacco Use Cessation

India
Massachusetts General Hospital
Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Genentech... and other collaborators

Completed

Preoperative Cisplatin and Bevacizumab in ER-, PR-, HER2 Negative Breast Cancer

Breast Cancer

United States
Dana-Farber Cancer Institute
Massachusetts General Hospital; Beth Israel Deaconess Medical Center; Genentech... and other collaborators

Terminated

Trastuzumab and Vinorelbine in Advanced Breast Cancer

Breast Cancer | Metastatic Breast Cancer

United States
Dana-Farber Cancer Institute
Massachusetts General Hospital; Beth Israel Deaconess Medical Center; Genentech... and other collaborators

Completed

Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases

Breast Cancer | Metastatic Breast Cancer | Progressive Breast Cancer

United States
Beth Israel Deaconess Medical Center
National Cancer Institute (NCI); National Institutes of Health (NIH)

Terminated

PD-1 Alone or With Dendritic Cell/Renal Cell Carcinoma Fusion Cell Vaccine

Renal Cell Carcinoma

United States
Dana-Farber Cancer Institute
Massachusetts General Hospital; Beth Israel Deaconess Medical Center; Genentech... and other collaborators

Completed

Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma

Lymphoma, Non-Hodgkin | MALT Lymphoma

United States
Mary-Ellen Taplin, MD
Sanofi; Beth Israel Deaconess Medical Center; Genentech, Inc.; Duke University

Completed

Neoadjuvant Bevacizumab Plus Docetaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy

Prostate Cancer | Adenocarcinoma of the Prostate

United States
Beth Israel Deaconess Medical Center
National Cancer Institute (NCI); Dana-Farber Cancer Institute; National Institutes...

Recruiting

Zafirlukast in Treatment of Marker Relapsed Ovarian Cancer

Ovarian Cancer

United States
Emory University
National Institute of Neurological Disorders and Stroke (NINDS); Hope for Depression... and other collaborators

Active, not recruiting

Deep Brain Stimulation for Treatment Resistant Depression With the Medtronic Activa PC+S

Treatment Resistant Depression

United States
Steven J Isakoff, MD, PhD
Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Abbott

Active, not recruiting

ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer

Breast Cancer | Metastatic Breast Cancer | BRCA1 Gene Mutation | brca2 Gene Mutation

United States
Dana-Farber Cancer Institute
Massachusetts General Hospital; Beth Israel Deaconess Medical Center; Novartis... and other collaborators

Terminated

Trial of PTK787/ZK 222584 Plus Paclitaxel

Metastatic Non-hematologic Malignancies

United States
University of California, San Francisco
Dana-Farber Cancer Institute; UCSF Benioff Children's Hospital Oakland; Alex's...

Completed

PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma

Sarcoma | Refractory Sarcoma

United States
Dana-Farber Cancer Institute
Massachusetts General Hospital; Beth Israel Deaconess Medical Center; Brigham... and other collaborators

Terminated

Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLL

Chronic Lymphocytic Leukemia | Small Lymphocytic Leukemia

United States
Dana-Farber Cancer Institute
Massachusetts General Hospital; Beth Israel Deaconess Medical Center; Georgetown... and other collaborators

Completed

Mifepristone (RU-486) in Androgen Independent Prostate Cancer

Prostate Cancer | Adenocarcinoma of Prostate

United States
Dana-Farber Cancer Institute
Massachusetts General Hospital; Beth Israel Deaconess Medical Center; Genentech... and other collaborators

Completed

Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer

Breast Cancer | Carcinoma of the Breast

United States
Dana-Farber Cancer Institute
Massachusetts General Hospital; Beth Israel Deaconess Medical Center; Genentech... and other collaborators

Completed

Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer | Papillary Serous Mullerian Tumor | Clear Cell Mullerian Tumor

United States
Dana-Farber Cancer Institute
Beth Israel Deaconess Medical Center; Brigham and Women's Hospital; Translational...

Completed

Upstaging of ALH/LCIS Found on Core Biopsy Based on Subsequent Excisional Biopsy

Breast Neoplasms

United States
Dana-Farber Cancer Institute
Massachusetts General Hospital; Novartis; Beth Israel Deaconess Medical Center; Oregon Health and Science University

Completed

The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer

Prostate Cancer | Metastatic, Androgen Independent Prostate Cancer

United States
Dana-Farber Cancer Institute
Massachusetts General Hospital; Beth Israel Deaconess Medical Center; Brigham... and other collaborators

Completed

Taxotere, Cisplatin and Irinotecan (CPT-11) for Esophagogastric Cancer

Gastric Cancer | Esophageal Cancer | GE Junction Cancer

United States
Ina-Respond
National Institute of Health Research and Development, Ministry of Health...

Completed

Integration of Mental Health in HIV Clinic to Increase the Success of ARV Treatment in PLWHA in Hospitals

Depression | HIV/AIDS

Indonesia
Dana-Farber Cancer Institute
Susan G. Komen Breast Cancer Foundation; Breast Cancer Research Foundation; Terri...

Active, not recruiting

DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC

Breast Cancer

United States
Massachusetts General Hospital
Dana-Farber Cancer Institute; Boston Children's Hospital; National Institutes... and other collaborators

Active, not recruiting

Proton Radiation for the Treatment of Pediatric Bone and Non-Rhabdomyosarcoma Soft Tissue Sarcomas

Bone Sarcoma | Non-rhabdomyosarcoma Soft Tissue Sarcoma

United States
Dana-Farber Cancer Institute
Patient-Centered Outcomes Research Institute; National Cancer Institute (NCI); Alliance for Clinical Trials in Oncology

Completed

Improving Informed Consent for Palliative Chemotherapy

Metastatic Colorectal Cancer | Metastatic Pancreatic Cancer | Unresectable Pancreatic Cancer

United States
Dana-Farber Cancer Institute
Massachusetts General Hospital; Novartis; Beth Israel Deaconess Medical Center; Brigham and Women's Hospital and other collaborators

Completed

RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors

Pancreatic Neuroendocrine Tumor

United States
Dana-Farber Cancer Institute
Massachusetts General Hospital; Sanofi; Beth Israel Deaconess Medical Center; Genentech... and other collaborators

Completed

Avastin and Taxotere for Esophagogastric Cancer

Gastric Cancer | Esophageal Cancer

United States
Massachusetts General Hospital
Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Brigham and... and other collaborators

Completed

Bortezomib Plus Rituximab for EBV+ PTLD

Epstein Barr Virus Infections | Post-transplant Lymphoproliferative Disease | Solid Organ Transplant | Stem Cell Transplant (Bone Marrow Transplant)

United States
Patrick Y. Wen, MD
Massachusetts General Hospital; Dana-Farber Cancer Institute; Brigham and Women... and other collaborators

Terminated

Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma

High Grade Glioma: Glioblastoma (GBM) | High Grade Glioma: Gliosarcoma | Anaplastic Astrocytoma (AA) | Anaplastic Oligodendroglioma (AO) | Mixed Anaplastic Oligoastrocytoma (AOA)

United States
Massachusetts General Hospital
Sanofi; Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Genentech... and other collaborators

Completed

Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder Cancer

Biliary Tract Cancer | Gallbladder Adenocarcinoma

United States
Massachusetts General Hospital
Bristol-Myers Squibb; Dana-Farber Cancer Institute; Beth Israel Deaconess Medical... and other collaborators

Completed

Cetuximab in Patients With Unresectable or Metastatic Hepatocellular Carcinoma

Hepatocellular Carcinoma

United States
Dana-Farber Cancer Institute
Massachusetts General Hospital; Beth Israel Deaconess Medical Center; Brigham... and other collaborators

Completed

Fulvestrant in Premenopausal Women With Hormone Receptor-Positive Breast Cancer

Breast Cancer

United States
Dana-Farber Cancer Institute
Janssen Pharmaceuticals; The Leukemia and Lymphoma Society; Multiple Myeloma... and other collaborators

Active, not recruiting

Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma

Smoldering Multiple Myeloma | Monoclonal Gammopathy

United States
David M. Jackman, MD
Massachusetts General Hospital; Beth Israel Deaconess Medical Center; Synta Pharmaceuticals...

Completed

Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer

Small Cell Lung Cancer

United States
David M. Jackman, MD
Beth Israel Deaconess Medical Center; Genentech, Inc.; Brigham and Women's Hospital

Completed

Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC

Non-small Cell Lung Cancer

United States
Beth Israel Deaconess Medical Center
Dana-Farber Cancer Institute; Genentech, Inc.; Brigham and Women's Hospital; Vanderbilt...

Completed

Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma

Kidney Cancer | Renal Cell Carcinoma

United States
Massachusetts General Hospital
Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Genzyme,... and other collaborators

Completed

Treatment of Older Adults With Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

United States
University Medical Center Groningen
Comprehensive Cancer Centre The Netherlands; Dutch Cancer Society; Dutch Institute... and other collaborators

Recruiting

Prediction Models for Complications After CRT in Esophageal Cancer (MODELS)

The Aim of This Project is to Develop and Validate NTCP-models for Complications After nCRT (and Surgical Resection)

Netherlands
Massachusetts General Hospital
Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Brigham and... and other collaborators

Completed

Partial Breast Irradiation (PBI) for Selected Patients With Early Invasive or Non-Invasive Breast Cancer

Ductal Breast Cancer

United States
Baylor College of Medicine
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Completed

Erythropoetin Neuroprotection for Neonatal Cardiac Surgery

Congenital Heart Disease | Hypoplastic Left Heart Syndrome | Transposition of the Great Arteries | Aortic Arch Hypoplasia or Interruption

United States
Ann & Robert H Lurie Children's Hospital of Chicago
Dana-Farber Cancer Institute; Fred Hutchinson Cancer Center; University of Minnesota

Completed

Development and Validation of a Symptom Scale for Children With Chronic Graft-versus-Host Disease (cGVHD)

Graft vs Host Disease

United States
Dana-Farber Cancer Institute
Bristol-Myers Squibb; Massachusetts General Hospital; Beth Israel Deaconess Medical... and other collaborators

Terminated

Cetuximab, 5-FU and Radiation as Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer

Rectal Cancer

United States

Clinical Trials Sponsored by Dina latif

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations